Safety/Efficacy of Rev M10 Vectors for HIV Gene Therapy

Nabel, Gary J.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Project (R01)
• Project #: 5R01AI036207-03
• Application #: 2072346
• Study Section: Special Emphasis Panel (SRC (45))
• Project Start: 1994-04-01
• Project End: 1997-12-31
• Budget Start: 1996-01-01
• Budget End: 1996-12-31
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: University of Michigan Ann Arbor
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 791277940
• City: Ann Arbor
• State: MI
• Country: United States
• Zip Code: 48109

Publications

Ranga, U; Woffendin, C; Verma, S et al. (1998) Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 95:1201-6

Flowers, C C; Woffendin, C; Petryniak, J et al. (1997) Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase. J Virol 71:2685-92

Fox, B A; Woffendin, C; Yang, Z Y et al. (1995) Genetic modification of human peripheral blood lymphocytes with a transdominant negative form of Rev: safety and toxicity. Hum Gene Ther 6:997-1004